Methods	Allocation: randomised. Blindness: double. Duration: 8 weeks.
Participants	Diagnosis: (CCMD-3) schizophrenia. N=61. Age: mean clozapine=30 years, mean olanzapine=25.8 years. Gender: 29 M, 32 F. Setting: in- and outpatient. History: duration ill mean= 4.2 years, age at onset not reported
Interventions	Clozapine: flexible dose. Allowed dose range: 25-400 mg/day. Mean dose: not reported. N=31. Olanzapine: flexible dose. Allowed dose range: 5-20 mg/day. Mean dose: not reported. N=30
Outcomes	Mental state: BPRS total score. Adverse effects: at least one adverse effect, extrapyramidal side effects (extrapyramidal symptoms), sedation, weight gain Unable to use: White blood cell countleukopenia (no usable data). Leaving the study early -adverse events (no usable data). Hypersalivation (no usable data).
Notes
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Unclear	Random, no further details.
Allocation concealment?	Unclear	No further details.
Blinding? All outcomes	Unclear	Double, no further details. Whether blinding was successful has not been examined, but both compounds differ quite substantially in side-effects. This can be a problem for blinding Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding. This latter, probably leads a low risk of bias
Incomplete outcome data addressed? All outcomes	No	Data on leaving the study early were not provided.
Free of selective reporting?	No	Data were not available for all of the predefined adverse effect outcomes
Free of other bias?	No	The sponsor was unclear. The upper dose range limit of clozapine was 400 mg/day which was reached rather quickly (10 days), which could mean a disadvantage for cloza-pine in terms of side-effects